1. Home
  2. BTCT vs CALC Comparison

BTCT vs CALC Comparison

Compare BTCT & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BTCT

BTC Digital Ltd.

HOLD

Current Price

$1.21

Market Cap

10.5M

Sector

Real Estate

ML Signal

HOLD

Logo CalciMedica Inc.

CALC

CalciMedica Inc.

HOLD

Current Price

$0.90

Market Cap

9.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BTCT
CALC
Founded
2006
2011
Country
Singapore
United States
Employees
26
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.5M
9.7M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
BTCT
CALC
Price
$1.21
$0.90
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
183.1K
296.5K
Earning Date
05-29-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.30
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$283.35
N/A
P/E Ratio
N/A
$2.97
Revenue Growth
N/A
N/A
52 Week Low
$1.07
$0.46
52 Week High
$4.47
$7.20

Technical Indicators

Market Signals
Indicator
BTCT
CALC
Relative Strength Index (RSI) 54.86 58.19
Support Level $1.25 $0.52
Resistance Level $1.36 $0.93
Average True Range (ATR) 0.09 0.12
MACD 0.02 0.01
Stochastic Oscillator 42.50 50.12

Price Performance

Historical Comparison
BTCT
CALC

About BTCT BTC Digital Ltd.

BTC Digital Ltd is the ledger technology that underlies bitcoin and other cryptocurrencies, based in the U.S., with a focus on bitcoin mining. A blockchain is a decentralized, distributed, and encrypted digital public ledger that stores information in a secure, verifiable, and permanent way. The company also generates revenue through the resale of mining machines, mining machine rental, and miner hosting services.

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.

Share on Social Networks: